Article
Endocrinology & Metabolism
Alice Boileve, Elise Mathy, Charles Roux, Matthieu Faron, Julien Hadoux, Lambros Tselikas, Abir Al Ghuzlan, Segolene Hescot, Sophie Leboulleux, Thierry de Baere, Livia Lamartina, Frederic Deschamps, Eric Baudin
Summary: This study aimed to evaluate the therapeutic strategy of locoregional treatments (LRT) combined with mitotane in patients with low tumor burden stage IVA adrenocortical carcinoma (ACC). The results suggest that the combination of LRT and mitotane can improve progression-free survival (PFS) and overall survival (OS) in this selected group of patients with ACC. The study also observed a significant number of complete responses in patients receiving mitotane plus LRT, highlighting the potential benefits of this treatment approach.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Li-Hsin Pan, Chueh-Chuan Yen, Chun-Jui Huang, Xin-Ning Ng, Liang-Yu Lin
Summary: This study aimed to characterize patients with adrenocortical carcinoma (ACC) in Taiwan and determine prognostic predictors of overall and progression-free survival. The findings showed that ENSAT stage, large vessel invasion, and mitotane use were significantly associated with overall survival. However, there were no independent predictors of progression-free survival.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Marilyne Daher, Jeena Varghese, Stephen K. Gruschkus, Camilo Jimenez, Steven G. Waguespack, Sara Bedrose, Lina Altameemi, Hadil Bazerbashi, Aung Naing, Vivek Subaiah, Matthew T. Campbell, Amishi Y. Shah, Miao Zhang, Rahul A. Sheth, Jose A. Karam, Christopher G. Wood, Nancy D. Perrier, Paul H. Graham, Jeffery E. Lee, Mouhammed Amir Habra
Summary: This study reports that the disease burden and clinical outcomes of adrenocortical carcinoma (ACC) have improved over the past two decades. More patients underwent complete surgical resection and received multiple lines of systemic therapy, indicating the importance of these advancements for guiding management strategies.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Massimo Terzolo, Martin Fassnacht
Summary: Surgery remains the most important therapeutic option for non-metastatic ACC, with the surgeon's expertise being more important than surgical technique. For patients at low risk of recurrence, active surveillance can spare them from unnecessary adjuvant mitotane treatment, while those at moderate-to-high risk should ideally enroll in the ongoing ADIUVO2 trial. Prospective multicenter trials are needed for long-term improvement of patient care.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Anna Calabrese, Soraya Puglisi, Chiara Borin, Vittoria Basile, Paola Perotti, Anna Pia, Paola Berchialla, Marco Volante, Cristian Fiori, Francesco Porpiglia, Andrea Veltri, Giuseppe Reimondo, Massimo Terzolo
Summary: The management of adrenocortical carcinoma (ACC) recurrences remains controversial. In this retrospective analysis, ACC recurrences were found to occur as a single lesion, multiple lesions in a single organ, or affecting multiple organs. Patients with a single lesion recurrence had a better prognosis, suggesting the use of locoregional treatments for ACC recurrence.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Oncology
Jesse E. Passman, Wajid Amjad, Jacqueline M. Soegaard Ballester, Sara P. Ginzberg, Heather Wachtel
Summary: Age, disease stage, surgical approach, and surgical margins are key factors affecting survival in patients with non-metastatic ACC. The extent of surgery and lymphadenectomy are not related to overall survival. In advanced disease, the open surgical approach is associated with improved survival.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Salvatore Grisanti, Deborah Cosentini, Marta Lagana, Alessandra Morandi, Barbara Lazzari, Laura Ferrari, Alberto Dalla Volta, Roberta Ambrosini, Vittorio Domenico Ferrari, Sandra Sigala, Alfredo Berruti
Summary: The Gem/Cape chemotherapy regimen shows modest activity in heavily pretreated patients with adrenocortical carcinoma. Clinical parameters such as neutrophil-to-lymphocyte ratio (NLR) and ECOG performance status are helpful in identifying patients who are unlikely to benefit significantly from this treatment.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Judit Toke, Andrea Uhlyarik, Julia Lohinszky, Julia Stark, Gergely Huszty, Tamas Micsik, Katalin Borka, Peter Reismann, Janos Horanyi, Peter Igaz, Miklos Toth
Summary: This study aimed to characterize the clinicopathological features and prognostic factors of a large cohort of Hungarian patients with adrenocortical cancer. The results showed that disease stage, mitotic activity, the resection state, and achieving therapeutic mitotane concentration were the most critical factors influencing the prognosis.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Andrea Abate, Elisa Rossini, Mariangela Tamburello, Marta Lagana, Deborah Cosentini, Salvatore Grisanti, Chiara Fiorentini, Guido A. M. Tiberio, Maria Scatolini, Enrico Grosso, Constanze Hantel, Maurizio Memo, Alfredo Berruti, Sandra Sigala
Summary: Ribociclib might induce apoptotic cell death and reduce cell proliferation rate through interfering with cell-cycle progression. The effect on cell viability is enhanced when combined with progesterone and/or mitotane.
Review
Oncology
Marco Lo Iacono, Soraya Puglisi, Paola Perotti, Laura Saba, Jessica Petiti, Claudia Giachino, Giuseppe Reimondo, Massimo Terzolo
Summary: Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma and is increasingly used for postoperative adjuvant therapy. It destroys the adrenal cortex, impairs steroidogenesis, and leads to cell death by deregulating cytochromes P450 enzymes, depolarizing mitochondrial membranes, and accumulating free cholesterol. The exact mechanism of mitotane's action is still unclear, and the variability in in vitro experimental conditions could impact the significance of identified molecular mechanisms.
Article
Oncology
Alessandra Mangone, Barbara Altieri, Mario Detomas, Alessandro Prete, Haider Abbas, Miriam Asia, Yasir S. Elhassan, Giovanna Mantovani, Cristina L. Ronchi
Summary: Inflammation-based scores calculated from routinely measured parameters may help predict response to chemotherapy in advanced adrenocortical carcinoma (ACC).
ENDOCRINE-RELATED CANCER
(2023)
Review
Oncology
Giuseppina De Filpo, Massimo Mannelli, Letizia Canu
Summary: This article focuses on current and future treatment options for adrenocortical carcinoma (ACC), emphasizing the importance of radical surgery and adjuvant mitotane for patients at high risk of recurrence. Chemotherapy options such as EDP-M, gemcitabine, and temozolomide are discussed. Limited data are available on second-line and third-line chemotherapy for patients with disease progression after EDP-M, with the efficacy of targeted therapies still under evaluation through clinical trials.
CURRENT OPINION IN ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Akihiro Ohmoto, Yasuyuki Shigematsu, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, Yasuyoshi Sato, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Yoshinobu Komai, Noboru Numao, Takeshi Yuasa, Junji Yonese, Junichi Tomomatsu, Kentaro Inamura, Shunji Takahashi
Summary: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Mitotane is the only approved agent for ACC treatment, but clinical data, especially in the Asian population, are scarce. A retrospective review of 10 ACC patients treated with mitotane showed a low overall survival rate. Further treatment strategies are needed to improve outcomes.
Article
Endocrinology & Metabolism
Y. S. Elhassan, B. Altieri, S. Berhane, D. Cosentini, A. Calabrese, M. Haissaguerre, D. Kastelan, M. C. B. Fragoso, J. Bertherat, A. Al Ghuzlan, H. Haak, M. Boudina, L. Canu, P. Loli, M. Sherlock, O. Kimpel, M. Lagana, A. J. Sitch, M. Kroiss, W. Arlt, M. Terzolo, A. Berruti, J. J. Deeks, R. Libe, M. Fassnacht, C. L. Ronchi
Summary: A points-based score (S-GRAS) has been shown to have superior prognostic performance in adrenocortical carcinoma (ACC) patients, independently from adjuvant mitotane treatment. The S-GRAS score provides a new important guide for personalized management of ACC.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Oncology
Rebecca Steenaard, Thomas M. A. Kerkhofs, Myrte Zijlstra, Floortje Mols, Michiel N. Kerstens, Henry J. L. M. Timmers, Rachel S. van Leeuwaarde, Koen M. A. Dreijerink, Elisabeth M. W. Eekhoff, Els J. M. Nieveen van Dijkum, Eleonora P. M. Corssmit, Ellen Kapiteijn, Marjolein N. T. Kremers, Richard A. Feelders, Harm R. Haak
Summary: This study included the first assessment of health-related quality of life in patients with adrenocortical carcinoma. It found that patients diagnosed more than 5 years ago had relatively good HRQoL with residual fatigue and emotional problems. Patients who underwent additional surgery or received mitotane or chemotherapy reported lower HRQoL and problems in various domains.
Article
Oncology
Dana M. Hartl, Abir Al Ghuzlan, Sophie Bidault, Ingrid Breuskin, Joanne Guerlain, Elizabeth Girard, Eric Baudin, Livia Lamartina, Julien Hadoux
Summary: Based on the study, prophylactic neck dissection (PND) may not be necessary for low-risk patients with intrathyroidal papillary thyroid carcinoma (cT1bT2cN0), as PND only upstages 8.6% of cases.
Article
Endocrinology & Metabolism
Alexandre Dormoy, Magalie Haissaguerre, Geraldine Vitellius, Christine Do Cao, Aurore Geslot, Delphine Drui, Helene Lasolle, Oceana Vieira-Pinto, Sylvie Salenave, Maud Francois, Marie Puerto, Helene Du Boullay, Anne Mayer, Anne Rod, Claire Laurent, Philippe Chanson, Yves Reznik, Frederic Castinetti, Olivier Chabre, Eric Baudin, Gerald Raverot, Antoine Tabarin, Jacques Young
Summary: This study evaluated the efficacy and safety of osilodrostat in patients with PNCS/EAS in France, and found that osilodrostat had significant efficacy in reducing hypercortisolism symptoms in these patients and was generally well tolerated.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
M. Bensiali, N. Anizan, S. Leboulleux, S. Lamart, E. Davesne, D. Broggio, A. Desbree, D. France
Summary: The OEDIPE software was developed with new functionalities to handle multiple 3D or planar images and a SPECT image for patient-specific dosimetry. Methods were implemented to recover patient biokinetics and validate the software using phantom images and whole-body retention data. Results showed good agreement between the estimated activities and cumulated activities from the software and reference values.
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
(2023)
Article
Oncology
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taieb, Stephane Bardet, Marie Terroir-Cassou-Mounat, Nadege Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurelie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, Martin Schlumberger, Abir Al Ghuzlan, Yan Godbert, Isabelle Borget
Summary: Dabrafenib-trametinib is effective for restoring iodine uptake in BRAF p.V600E-mutated DTC patients, with a 6-month partial response observed in 38% of patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
Kamel Mohammedi, Jerome Bertherat, Gerald Raverot, Delphine Drui, Yves Reznik, Frederic Castinetti, Philippe Chanson, Manon Fafin, Julie Brossaud, Antoine Tabarin
Summary: This study assessed the long-term cortisol exposure in medically treated Cushing disease (CD) patients by measuring the levels of hair cortisol and hair cortisone. Despite normalized urinary free cortisol levels, a subset of patients still displayed altered circadian rhythm of cortisol secretion.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, Isabelle Borget
Review
Pathology
Agata Czarnywojtek, Krzysztof Pietronczyk, Lester D. R. Thompson, Asterios Triantafyllou, Ewa Florek, Nadia Sawicka-Gutaj, Marek Ruchala, Maria Teresa Plazinska, Iain J. Nixon, Ashok R. Shaha, Mark Zafereo, Gregory William Randolph, Peter Angelos, Abir Al Ghuzlan, Abbas Agaimy, Alfio Ferlito
Summary: This article presents a comprehensive review of Riedel thyroiditis (RT), focusing on its etiology, diagnosis, and management. The literature was reviewed using three databases: PubMed, Sinomed, and China National Knowledge Infrastructure. The histopathological features of RT resemble a localized form of IgG(4)-related systemic disease (IgG(4)-RSD). The initial diagnosis of RT is based on clinical history and imaging, followed by confirmation through histopathological examination. Glucocorticosteroid therapy is currently considered the first-line treatment for RT, with immunomodulatory agents used for disease relapse.
Review
Endocrinology & Metabolism
Paulina Kuczma, Marco Stefano Demarchi, Sophie Leboulleux, Christophe Tresallet, Maria Mavromati, Reza Djafarrian, Andrea Mabilia, Frederic Triponez
Summary: The most common site of lymph node metastases in papillary thyroid carcinoma is the central compartment of the neck (level VI). Prophylactic surgical clearance of the level VI in the absence of clinically suspicious lymph nodes (cN0) is still under debate. Arguments against the prophylactic central lymph node dissection (CLND) cite minimal oncologic benefit and concomitant higher operative morbidity. Recently, near-infrared fluorescence imaging has emerged as a potential tool to minimize the risk of hypoparathyroidism associated with CLND.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Fernando Lopez, Abir Al Ghuzlan, Mark Zafereo, Vincent Vander Poorten, K. Thomas Robbins, Marc Hamoir, Iain J. Nixon, Ralph P. Tufano, Gregory Randolph, Pia Pace-Asciak, Peter Angelos, Andres Coca-Pelaz, Avi Khafif, Ohad Ronen, Juan Pablo Rodrigo, Alvaro Sanabria, Carsten E. Palme, Antti A. Makitie, Luiz P. Kowalski, Alessandra Rinaldo, Alfio Ferlito
Summary: In non-well differentiated thyroid cancer, the rate of nodal involvement varies depending on the histology of the tumor. Treatment for anaplastic carcinoma, medullary carcinoma, and poorly differentiated carcinoma of the thyroid is well-established. However, treatment for other rare tumors needs to be individualized based on histology and anatomical distribution. The rate of lymph node involvement in non-well differentiated thyroid cancer is variable. Different types of thyroid cancer require different approaches to neck management.
Article
Cell Biology
Saad Nadeem, Matthew G. Hanna, Kartik Viswanathan, Joseph Marino, Mahsa Ahadi, Bayan Alzumaili, Mohamed-Amine Bani, Federico Chiarucci, Angela Chou, Antonio De Leo, Talia L. Fuchs, Daniel J. Lubin, Catherine Luxford, Kelly Magliocca, German Martinez, Qiuying Shi, Stan Sidhu, Abir Al Ghuzlan, Anthony J. Gill, Giovanni Tallini, Ronald Ghossein, Bin Xu
Summary: This study evaluated the performance of three counting techniques for the Ki67 index in medullary thyroid carcinoma and found that all three methods correlated near-perfectly with manual counting. Medullary thyroid carcinomas with a high Ki67 index were associated with decreased survival rates. The study validated the effectiveness of machine learning and image analysis software in generating accurate automatic Ki67 proliferation indices in medullary thyroid carcinoma.
Article
Obstetrics & Gynecology
Georgios E. Papadakis, Benedicte de Kalbermatten, Alexandre Dormoy, Sylvie Salenave, Severine Trabado, Oceana Vieira-Pinto, Carine Richa, Peter Kamenicky, Philippe Chanson, Luigi Maione, Nelly Pitteloud, Jacques Young
Summary: Cushing's syndrome (CS) affects the gonadotrope axis and testicular functions differently depending on the intensity of hypercortisolism and underlying etiology. Excess cortisol caused by CS leads to varying degrees of hypogonadotropic hypogonadism (HH), with more severe impairment in men with intense hypercortisolism associated with paraneoplastic/ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS).
HUMAN REPRODUCTION
(2023)
Article
Endocrinology & Metabolism
Arnaud Jannin, Fabiola Giudici, Christelle de la Fouchardiere, Abir Al Ghuzlan, Johanna Wassermann, Cecile N. Chougnet, Delphine Drui, Yann Godbert, Frederic Ilouz, Stephane Bardet, Sylvie Zanetta, Nathalie Roudaut, Marie Batisse Lignier, Lionel Groussin, Marc Klein, Slimane Zerdoud, Livia Lamartina, Eric Baudin, Myriam Decaussin-Petrucci, Emmanuelle Leteurtre, Francoise Borson Chazot, Christine Do Cao, Isabelle Borget, Julien Hadoux
Summary: This study evaluated factors associated with overall survival of patients with anaplastic thyroid carcinoma (ATC) in France. Factors such as disease stage, multimodality treatment, synchronously transformed ATC, and neutrophil-to-lymphocyte ratio were found to be independently associated with improved OS in patients with ATC. Long-term OS was observed in selected patients with ATC who underwent multimodal treatment.
Article
Biochemistry & Molecular Biology
Salma Fenniche, Mohamed Oukabli, Yassire Oubaddou, Hafsa Chahdi, Amal Damiri, Abir Alghuzlan, Abdelilah Laraqui, Nadia Dakka, Youssef Bakri, Corinne Dupuy, Rabii Ameziane El Hassani
Summary: The expression of NOX4, a reactive oxygen species-generating NADPH oxidase, was found to be upregulated in PTC-BRAF(V600E) tumors compared to PTC-BRAF(wt) tumors based on TCGA data. However, the protein level expression of NOX4 in malignant and non-malignant tumors has not been analyzed. In this study, we used immunohistochemistry staining to examine NOX4 protein expression in different types of thyroid tumors and non-malignant diseases. The results suggest a positive correlation between the BRAF(V600E) mutation and NOX4 expression, and NOX4 may serve as a complementary biomarker for aggressiveness in PTC.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Article
Endocrinology & Metabolism
Maria Mavromati, Thomas Mavrakanas, Francois R. Jornayvaz, Karl Schaller, Aikaterini Fitsiori, Maria I. Vargas, Johannes A. Lobrinus, Doron Merkler, Kristof Egervari, Jacques Philippe, Sophie Leboulleux, Shahan Momjian
Summary: This study assessed the impact of transsphenoidal surgery on pituitary function in patients with non-functioning pituitary adenomas (NFPAs) and identified predictive factors. The results showed that the recovery rate of pituitary deficiency after surgery was 46% and the rate of new pituitary deficiency was 10%. Male patients and patients with hyperprolactinemia were more likely to experience pituitary function recovery. Rating: 8/10
